Biovation's DeImmunization

Immunogenicity reduces efficacy of therapeutic proteins and has made it difficult to develop such molecules. Biovation Ltd. says its DeImmunization technology, which modifies T cell epitopes responsible for immunogenicity, can help solve this problem.

Last week, Biovation announced a

Read the full 388 word article

How to gain access

Continue reading with a
two-week free trial.